Q3 2019 Earnings Call
Good afternoon, ladies and gentlemen, and welcome to the Q3 2018 Perkin Elmer earnings Conference call. At this time, all participants are on a listen only mode.
Later, we will conduct a question and answer session and instructions will follow at that time.
If anyone should require assistance during the conference. Please press Star then zero on your cats tone telephone I would now like to turn the conference over to your host Mr. Bryan Kipp, Vice President of Investor Relations. Please go ahead.
Thank you Angela good afternoon, and welcome to the Perkinelmer third quarter 2019 earnings Conference call with me on the call or Rob Friel, Chairman and Chief Executive Officer, a lot thing President and Chief operating Officer, and Jamie Mock Senior Vice President and Chief Financial Officer.
If you have not received a copy of our earnings press release, you may get one from the Investor section of our website at Www Dot Perkinelmer dotcom.
Please note this call is being webcast live and will be archived on our website until November 13 2019.
Before we begin we need to remind everyone of the safe Harbor statements that about that have outlined in our earnings press release issued earlier this afternoon and those interested to see FCC filings statements or comments made on this call maybe forward looking statements, which may include but are not necessarily limited to financial project.
Tons or other statements of the company's plans objectives expectations or intentions. These matters involve certain risks and uncertainties. The companys actual results may differ significantly from those projected or suggested by any forward looking statement due to a variety of factors, which are discussed in detail interest.
He filings any forward looking statements made today represent our views only as of today, we disclaim any obligation to update forward looking statements in the future even if our estimates change. So you should not rely on any of today's forward looking statements as representing our views as of any other date after today.
During this call we were referring to certain non-GAAP financial measures a reconciliation of the non-GAAP financial measures. We plan to use during this call to the most directly comparable GAAP measures is available that's an attachment to our earnings press release to the extent, we use non-GAAP financial measures. During this call that are not reconciled to GAAP.
In that attachment, we will provide reconciliations promptly I'm now pleased to introduce the chairman and Chief Executive Officer of Perkinelmer, Rob Friel, Rob Thanks, Ryan and good evening, everyone. The third quarter was a busy one for Perkinelmer, which we continued to taking important steps to position the company for acceleration of our growth.
In profitability, while also delivering strong financial results.
Turning first to our financial results in the quarter revenue was 707 million representing organic revenue growth of 5%.
Adjusted EPS was one dollar and six cents, an increase of 18% over Q3 last year and significantly exceeding our forecast.
The benefits of our new operating model and increased contributions from our growth businesses delivered very significant operating leverage.
The strong margin expansion is giving us confidence to raise or full your your adjusted EPS growth to 13%.
Right stronger than anticipated headwinds from foreign exchange in a challenging macroeconomic environment.
Now for a lot of Jamie will discuss the specifics overperformance in the end markets overall market conditions for the majority of our portfolio are consistent with our previous outlook, except for two areas. We will discuss our businesses are performing well.
Importantly, our key growth areas are continuing to gain traction in scale and remain on track to achieve or exceed our previously communicated goals for 2019.
At the sort of this year I just go see opportunity we sold to increase are impacting growth by better leveraging the intersection in synergies of our technical and commercial capabilities across perkinelmer.
During the third quarter, we completed a fairly significant organizational realignment to create a more unified approach the customers.
Better facilitate color collaboration across the company. In addition, during the quarter, we announced the appointment of provide a CEO effective the ended this year as rose several other business and functional leadership changes.
These actions are the final steps in the execution of a multiyear strategy to position the company organizationally for the next phase of its evolution and grow growth.
During the quarter. We also added a key strategic asset to our food capabilities with the addition of the Amazing group, increasing our product and technology, Brad as well as commercial resources in trying to promote will going back was the acquisition in more detail. However, strategically this deal was consistent with our reach it reached.
Insist bio purchase as it is focused in an attractive end market increases our consumable mix and expands our scientific and technological capabilities and adjacent technologies.
Also similar to assist bio we believe Meiji will bring it provide very attractive financial returns given the natural channel and geographic synergies between our two companies.
Additionally, during the third quarter, we issued an $850 million 10 year bond and extended the term a revolving credit facility. These actions strengthen our financial position by securing long term capital at very attractive rates, while also increasing our capacity for both organic and inorganic investments.
The last item I will highlight for the third quarter is a significant operating leverage we experienced this quarter.
As we outlined previously the key actions for 2019 in 2020 to meet our operating margin objectives, we're focused on increasing the incremental margin flow through on revenue growth to 20%.
So an emphasis on improving your muse margins and reducing our sq data to 24% of revenue by 2020.
As many of you know driving sustainable margin improvement often requires efforts to simplify processes and improved supply chains that must be implemented several quarters before they are evident in financial results.
Sequentially, it's great to see that the many actions we've taken over the prior several quarters are beginning to translate into improved profitability.
Specifically, our incremental margins for the third quarter in full year are tracking significantly above our plan and in particular your from your margins year to date over a year ahead of our acquisition model.
Similarly in the third quarter adjusted achieved a as a percentage of revenue was below 24% and year to date. We are trending ahead of our 2020 plant.
While we are proud to progress we've made this year, we view this as a never ending journey to become a more efficient and streamlined organization.
However, the results this quarter further reinforce our belief that there is a significant opportunity to further increase operating margins of the company, while maintaining ample capacity to appropriately investing growth.
So to summarize both the third quarter and performance year to date.
Organic revenue growth of 5% has been about 100 basis points below our guidance due to market headwinds in the applied markets and some timing of revenue in diagnostics, neither of which we believe present mid or long term challenges to our high single digit revenue growth model. In addition, despite the lower revenue.
Operating margins and adjusted EPS are tracking ahead of plan as our margin improvement plans are yielding greater benefits than anticipated.
Therefore, as we put our plans together for the next several years, we're quite optimistic as our growth businesses like your immune then it is our genomics business service informatics and cannabis continue to do very well also the three bolt on acquisitions completed this year the completion of our commercial realignment.
As well as our improved operating leverage should further increase organic revenue growth and profitability.
I will now turn the call over a prolonged who will discuss in more detail. Some of these specific items and our optimism about the future of Perkinelmer. However, before I introduce prolonged I didnt want to recognize that as I will be stepping down as chairman and CEO at the end of this year. This will be my last earnings call for Perkinelmer, Therefore, I would like.
Take this opportunity to thank all of you for your support of me and the company over the years I feel very fortunate to have had the opportunity to get to know and work with all of you wish you all continued success.
And now we're very happy to turn the call over to the next CEO Perkinelmer plod, saying.
Thank you Rob.
Before I begin my prepared remarks, I wanted to take a few minutes to acknowledge and time crop part as leadership in service to bucket number.
As you know Robin Buda, starting from the company and this is as last quarterly earnings call.
For those of us keeping tabs. This is has 84.
Earnings call that bucket another maher.
Rob has evolved broken out into a strong company for the legacy of sustainable and profitable awnings growth and optimize the portfolio towards high growth end markets.
The management team at broken out of mobile build on the has legacy to progress broken out about two its next level as a growth focused company, providing high quality earnings.
Today I'm excited to update everyone on the continued progress we have made on our strategic priorities during the third quarter.
But to start off I want to begin with some details of our recent acquisition of the Amazing group.
We are extremely excited to welcome the team from moves on to Buck in Alabama, Mason is a highly attractive and strategic asset.
One definitely a pivotal role in our domestic food strategy in China as far as our broader long term food strategy across the globe.
Mason has developed a reputation as a leading food safety testing company in China.
Due to its gotten portfolio park strong culture of innovation and unparalleled customer intimacy.
Companies headquartered in Beijing, and has a broad commercial presence in China supported by 140 direct sales and marketing feet on the street.
Many thanks comprehensive technology and product portfolio covers immuno assay microbiology and molecular testing for food safety and prioritized end markets grain Beatty meat and seafood.
With the addition of meson, we estimate that the total addressable market for our food portfolio in China is now $1 billion to $2 billion and we have the most extensive set of capabilities across the food dusting value chain.
For example in baby, we now have the broader set of food quality and safety capabilities, which span from upstream hard management, the midstream collection Center testing.
Transfer station and storage testing.
Additionally, we also now sorry, UQM QC labs are processing facilities, and part parties safety and regulatory adherence testing customers.
We estimate that the overall, China food safety testing market has been growing at a low double digit Gallagher over the past five years, driven by increasing government regulation and enforcement changes in local died to do preference and these rising middle class.
And we expect that the market to continue to grow Harvey high single low double digit clip for the foreseeable future.
Since Maison was founded in 2009, the company has grown its top line revenues at a greater than 25% CAGR.
More importantly, 75% of meetings revenue comes from reagents and consumer birds and is as important to micro cyclicality.
With the addition of Mazer, we will now have more than 80 million dollar food quality and food safety testing business in China.
We see significant synergy opportunities from a portfolio, China and regulatory standpoint, missing has developed strong connections with major regulatory bodies and key opinion leaders and the company counts many of the leading local food companies as customers.
On the rich view as critical in the country still in the early innings of establishing national an industry standards.
Why did the downstream food quality and market has been soft globally. This your upstream food safety testing has been solid and we continue to view overall fuel quality and safety testing as one of the most attractive end markets globally.
Due to its long term structural tailwinds, it's a regulated nature and the fact that the market. This highly fragmented with no dominant player across the value chain.
We believe the acquisition of Mays AR VR now in a prime position to establish ourselves as a leader in food quality and safety testing over the coming years.
Switching over to the TARP quarter performance and an update on our strategic priorities.
Echoed rob's enthusiasm.
We've continued to make tremendous progress shaping our organization.
Internally to leverage our capabilities across spoken Alamo and provide a better customer experience.
The customer experience from the team has made good progress leveraging cross functional expertise across spoken on those.
Focused business segments, food diagnostics life Sciences, and applied markets as well as informatics.
For example, Vietnam able to provide turnkey solution for cannabis customers that color on testing analytical lab management and data analytics need to ensure the quality and safety off their products and meet compliance requirements.
Let us do some elements of these cannabis workflows solutions that will be rolled out over the coming quarters, but the team has had success during the top quartile cross selling additional bucking Alamo products to share of one example.
Can I think that faster turnaround times and higher accuracy sample prep increasingly important needs in the cannabis industry.
I wondered kind of his team leaders connected customers.
Members of our applied genomics team.
<unk> Dawn Doubleclick cannabis specific well flow to sell alongside a complete analytical offering.
John This GTC liquid handling Walkstation was recently adopted but and then be as new testing lab in Vancouver to automate the primary sample transfer and sample set up for the analysis of contaminates such as more spores on pesticides.
In cannabis, which is extremely important for medical users, who could potentially have compromised immune systems.
Turning to our priorities our people and culture, we finalized our commercial organization realignment during the quarter.
As I mentioned on our last earnings call aligning our commercial structure by region has been a key initiative. This year, we firmly believe that empowering the regions with decision, making closer to the customer is that I play book as it puts the Weiss of the customer at the center off our commercial strategy.
Finally on innovation Vanda this continues to gain traction.
Inbound inquiries have increased following the prenatal diagnostics publication in late August .
There is significant interest in our technology as Vanda this is high sensitivity and specificity and low no called rate resonates with clinicians.
To date, we have 19 systems installed on in the process of installation and we remain on track to achieve on your end goal of Cardi installations, our pipeline of opportunities over the next six months remains very healthy.
Additionally, as we announced in a press release yesterday up Pittsburgh in Malaysia Labs can now receive samples to perform and IBP testing in support of our Mcdonnell UNFI to help customers.
In the U.S. The aim of the Pittsburgh Glass is also too so as a backup for clients requiring overflow capacity as well as an outsourced service lapsed for small customers will need to scale before they bring technology in house.
We also will be offering carrier screening and preeclampsia testing, which along with advantages as the forced to market combined offering.
So to further differentiate us in the U.S. market and provides a much better customer experience.
Yes, Validus is now up and running out of Pittsburgh Lab, you got excited to announce that we will be hosting a tour at that facility in the near future.
Given the capacity constraints at the lab, we will only be hosting the sell side during the day, but we hope to be able to host investors at the facility down the road as vote will send out official invites in the coming weeks.
As I said on our last call I'm inspired to witness the immense talent in our organization rallying together to achieve the vision of becoming it truly differentiated player.
By leveraging our capabilities across our organization to provide a flawless customer experience.
I believe you out in a good position to close out of 29 team on a solid footing, which will set us up valid heading into 2020.
I look forward to sharing ongoing progress with you as we achieve our mission and accelerate profitable growth.
I will now turn the call over to Jamie.
Thanks for a lot and good evening everyone.
As always I want to start with the highlights for the quarter next I'll provide some additional color on our served end markets and detail on other financial metrics.
Lastly, I'll finish by providing a brief update on how we're thinking about the fourth quarter. Overall, we're pleased with our third quarter results in year to date performance to start market conditions were largely inline with our expectations entering the quarter and our growth accelerators continued to perform well.
For example, your own immune continued to grow at a double digit clip due to strong demand in China.
Can I Miss in genomics testing remain on pace to meet or exceed our initial goals for 2019.
And then its momentum continues to build following the prenatal diagnostics publication in late August .
As Robin for lot of mentioned, we completed and are excited about the acquisition of measuring which I will cover in greater detail later.
Additionally, prior actions to reduce our organizational complexity has made us a nimbler organization moving forward.
Finally, we are raising our 2019 earnings estimate to the high end of our prior range or $4.07 per share, which represents a three cents increase versus the midpoint of our prior range.
In summary, the team has done a great job executing on our near and long term priorities.
Turning to the third quarter results, we continue to be pleased with the strengthen our business as organic revenue grew 5%.
Reported revenue grew 5% to 707 million and included 2% foreign exchange headwind and a 2% net acquisition tailwind.
By business diagnostics, representing 40% in total sales grew 6% organically driven by our immuno diagnostics and reproductive health business lines.
Discovery and analytical solutions, representing 60% and total sales grew 4% organically highlighted by continued strength in life Sciences, and offset by ongoing tepid demand in the applied markets.
I will provide some additional color on both businesses in a moment.
On a geographic basis organic growth trends remained mixed as they have throughout the year 2019.
Asia Pacific and Europe grew mid single digits, while the Americas grew low single digits.
Year to date, the Americas and Asia Pacific are up mid single digits, while Europe was up low single digits.
Operationally, we are extremely pleased with our performance in the third quarter and we continue to see significant potential to improve our profitability going forward.
Adjusted operating margins expanded 250 basis points in the third quarter to 21.6% driven by productivity mix and cost out actions.
Year to date, we've expanded adjusted operating margins by 150 basis points year over year.
As Rob mentioned adjusted earnings per share of a dollar and six cents was an increase of 18% versus the third quarter of 2018 and five cents ahead of our guidance.
Looking further into the key drivers within our segments, let's start with our diagnostics business.
As mentioned in my earlier remarks organic revenue grew 6% driven primarily by our immuno diagnostics and reproductive health franchises.
On the Immunodiagnostics fun euro immune and Tulip led the way as both grew at a healthy low double digit organic growth rate.
Your immune was broad based with auto immune allergy and infectious disease testing all growing double digits during the quarter.
Geographically, China remains strong while you're on mute U.S. business also continues to scale.
Rapidly growing at a very healthy double digit rate.
Thing went live during September at a large reference lab. Therefore, we continue to expect Euronews us market share for M&A testing to reach 50% as testing ramps up moving forward.
Reproductive health grew mid single digits organically, driven by our genomics testing business and expanded coverage in Asia Pacific.
As one example from earlier this year, the Philippines implemented an expanded newborn screening program.
The National Insurance company fill health announced that it will provide 100% public insurance reimbursement for all newborns.
Previously only 12% of newborn screening and payment was all out of pocket.
By the end of September and estimated 85% of newborns were screened under the new program.
[laughter] applied genomics growth moderated versus the first half trends down mid single digits in the third quarter comparisons in the business were difficult due to the timing of some high ASP large automated workstation purchases last year.
We continue to see a healthy expansion in our opportunity funnel, which keeps us encouraged that this business will return to healthy growth.
Turning to discovery and analytical solutions organic growth of 4% was a 2% uptick versus the first half performance.
By end market, we experienced high single digit organic revenue growth and pharma biotech.
Propelled by our imaging detection and informatics product lines, both were up double digits in the quarter.
Our informatics business continues to perform well as leading pharma and biotech companies actively shifts to modern future proof workflow solutions like perkinelmer signals to accelerate their R&D insights.
The applied markets were flat in the quarter, driven primarily by softness in China, and Europe , which were down mid single digit and low single digits respectively.
Combined overall industrial environmental was flat and improvements sequentially. However, we think the improvement as a function of easier comparisons on a sequential basis, not a fundamental improvement and the underlying market trends.
It was up low single digits bolstered by strong cannabis demand.
Shifting to below the line items adjusted net interest and other expense for the third quarter was approximately $15 million an adjusted tax rate was approximately 14% driven by benefits from global tax planning actions.
Turning to the balance sheet, we finished the quarter with approximately $2.3 billion of debt and 393 million of free cash flow of cash free cash flow in the quarter was 9 million and adjusted free cash flow in the quarter was 96 million.
As a reminder, the difference between reported and adjusted number is due to cash payments associated with prior acquisitions.
Actions to improve working capital have been put in place and as a result sequential usage has improved versus the first half performance.
We anticipate additional improvement in the fourth quarter and into 2020.
As mentioned we are excited about our messaging acquisition the net purchase price was approximately $152 million.
We expect a double digit return on invested capital by year for we estimate managing to approximately have $30 million revenue in 2019 with accretive operating margins.
For the fourth quarter, we expect meeting to contribute less than 1% to perkinelmer revenue growth and negligible EPS accretion.
For modeling purposes, the acquisition officially closed October 17th.
Over the course of the last 45 days, we refinanced a substantial portion of our debt. We were pleased with the pricing of our new 850 million dollar tenure bond in the extension of our revolving credit facility.
We reduced our cost of debt by 50 basis points more than doubled our overall maturity profile and alleviated our 2021 maturity cliff risk.
Finally, we exited the quarter with a net debt to adjusted EBITDA ratio of approximately 2.8 times and we expect to end the year at approximately that same level.
Closing the books on the first nine months of 2019, we remain pleased with our performance, including 5% organic growth.
13% growth and earnings per share and continued success of our growth accelerators.
Additions of measuring Ansys bio will help accelerate our growth in coming years, and improve our reagent portfolio and capabilities.
The new organizational structure will further strengthen our ability to execute on a consistent basis.
For the year, we now expect 5% organic growth and reported revenue to be approximately $2.8 billion, including 68 million from far from foreign exchange headwinds and approximately 41 million of contributions from acquisitions and divestitures.
We are increasing our full year EPS guidance adjusted EPS guidance to $4 in seven cents, which includes an incremental two cents headwind from foreign exchange compared to our prior guidance.
Additionally, we now expect to expand our operating margins by 150 basis points.
Finally, we anticipate 60 million and adjusted interest and other expenses.
13% to 14.5% tax rate and our share count to remain at slightly under $112 million for the year.
For the fourth quarter of 2019, we are forecasting reported revenue of $800 million, representing 5% organic revenue growth, including a foreign exchange headwind of approximately $11 million versus the comparable prior period.
In terms of adjusted earnings per share gains for Q4, we are forecasting $1.32.
Before I turn the call back to the operator, I'd also like to congratulate Rob on an enormously successful career.
In addition to for Latin marks on Rob's transformation of the company. He is also positively impacted the lives of thousands of employees and their families along the way including myself.
From all of US we thank you and wish you a relaxing and wonderful retirement. This concludes my prepared remarks, operator at this time, we would like to open the call for questions.
Ladies and gentlemen, if you have a question at this time. Please press the star the number one key on your Touchtone telephone. Your question has been answered I agree with your move yourself from Q. Please press the pound key please limits and just one question and one follow up question. Thank you.
Okay.
Your first question comes from the line of Derik Debruin with Bank of America. Please go ahead.
Hi, good afternoon.
Yes.
Yes, hi, Jack So I'm still.
Still not so much clear on diagnostics slowdown in the quarter. I mean, you did 9% first half the year, 6% this quarter and it was on easier comp can you just walk through what did a sequential deceleration wise in the quarter.
Yes, the two aspects to it Derek you know one is as we are moving be genomics testing lab, we had two facilities one in brand far and one in Pittsburgh and via consolidating that into Brett spark. So from the move that has resulted in a backlog of samples which were not.
Through and that contributed to a due to some of the slowdown on the diagnostics. One the second one was that on the applied genomics business. We had last year a lot of capital based systems on the automate the on the automation side of it which did not come through.
And that has postponed to want to the next few quarters again. These are things that we it's not that we have lost fees, but they have moved on into the next couple of quarters. So that essentially has accounted for the slowdown that we saw on on Q3.
Again coming back to an odd reproductive health franchises and Immunodiagnostics those continue to do ready about despite the slowdown and bought trades.
Right. So if you adjust for those two items what was that what we've got about what was the hit organic revenue growth science, it's about 3%.
Yes, that's right Eric that would get you back to about the 9% run rate.
Great. Thank you.
And.
Yes.
Yes, one follow up question on this one.
Did you book that you look to margin expansion, which is really impressive any you see is that as seen in our sustainable going forward.
Yeah.
Let me take that there again I mean, when I when I think about margin expansion I think this has been as Rob mentioned in his prepared remarks years of planning around this and a lot of times. It just takes some time to kind of show up in our margin line.
I think we talk about three general levers all of them playing a role as teenager point being one of them, but I mean, I think mix has been better so a little bit more diagnostics, even within das our life Sciences business is growing informatics and reagents continue to grow with regard to leverage to your question. Yes, I mean, I think we have made the necessary and.
Estimates in years prior and we anticipated that we'd be able to take down the SGN as a percent of revenue.
All of it and we also had some improvements due to the synergies and our reorganization and so that helped a little bit here as well and then on productivity I think we've all got a lot going on both from a shot perspective of services perspective, as well as indirects as well so.
We can elaborate more on those but I think it is sustainable here or there might be a little bit of timing, but not much of it.
Great. Thanks, Rob Happy Trail and good luck.
Thank you.
Your next question comes at a line of Polyimide with Janney. Please go ahead.
Hey, Rob Congratulations and a you know when I first started covering you 19 years ago.
5% organic or mid single wasn't even on the horizon for a perkin.
Could you kind of replay want a you did as you became CEO and you know as you stand here today.
Could you kind of reflect on you know where do you think per tonne stands and kind of take about for what the investment you've done on R&D and M&A in divestiture. If you could you know.
Can summarize that up and be awesome, yeah, I'd be happy to do that and Paul you're probably one of the few people that are sort of remember the.
The old days there in the early two thousands, but but anyways you can imagine not surprisingly over last couple of weeks I've been a little bit more reflective all my tenure here and I would say I feel really good about what we've been able to accomplish that the company during the sort of almost two decades and I really want to emphasize the we part of that statement as I've been.
Extremely fortunate to work with really some some outstanding people over the years and.
As I think about the most important accomplishments. This is probably three or four I I'd sort of just spike out quickly. One obviously that's relevant for this audience is the.
The value we've created for our shareholders. If I go back to when I started as CFO in 99, the company had a little north of $1 billion in market cap.
And I became CEO in early 2008, it had grown to three and today, we sit at just under 10.
Within enterprise value of close to 12 and sort of put that in perspective, if you had invested $1 billion in the market in 99 you'd be at about.
3 billion meeting over that period of time, we've created about 7 billion and incremental value four of which was.
During my tenure as CEO and I think an important component of that value creation. As you mentioned Paul was the dramatic shifts in the portfolio.
And capabilities as a company.
It's been particularly I would say in the last six or seven years and <unk>.
And if you, particularly proud that we've been able to do that with fairly minimal disruption in for those of you.
That had been around for a while it's a it's really dramatic change of our end markets, our geographic footprint or technological capabilities.
Well, that's not only provides I would say a better platform to accelerate the growth and profitability. It's created a more unifying mission.
The purpose for the company around improving health globally, and that really takes me to the third area where.
Really feel great about the organizational capability capability, we've built in.
And that sort of things like work environment in culture, and why people to come the Perkinelmer and.
In the past I would say you know I felt like the company.
Attracted people because more or less the job and we sort of a transactional relationship and.
They came here to work and receive a paycheck and that was sort of it I don't think.
People come the Perkinelmer as a place to participate in Michigan at the same time pursue sort of a career.
And as a result, I think would really start to differentiate us is how our employees take a more carrying a longer term approach through what they do and how they do it and then.
Last thing I just mentioned is.
As we sort of reaches transition point I feel extremely proud of the condition of the company I think we're fortunate to have per lot has our next CEO . He knows company, where you've been part of the significant changes at the company over last five years.
I feel like will be supported by an excellent leadership team and as a Jamie and Paul talked about the recent commercial realignment I think it allows us to better serve our customers and.
And in fact infuse more simplicity in how we operate so.
I feel like whether you look at the company from a financial perspective strategic position or upper issues. Just it's just never been in a better placement. So mix, it's an exciting time for the company and it should be for our shareholders customers employees. So.
Anyway.
I apologize for the long answer, but I feel like I've been here, a long time and there's lot of good things to talk about so.
Anyway, it's been it's been a good run and I feel like it's turned over some great hands and excited about future.
Thanks, Rob and thanks for the incremental 7 billion and it's been a great Ron Thank you.
Thanks.
And your next question comes in all honesty, whereby from Cleveland Research. Please go ahead.
Hi, Good evening, Thanks for taking my question and Rob I wish you a wonderful retirement.
A couple of questions for you I guess first Jamie could you talk a little bit there were some larger one time charges. This quarter. The one that stuck out to be was the accelerated.
Executive comp just kind of any color on that and then just also if you could talk within the deep gas business kind of how your instruments business versus services group in the quarter.
Instruments versus services out you said on the second one there Steve.
Yes, exactly with yeah exactly yes, so with regards to the accelerated CEO charge in conjunction with Rubs announced retirement the board agreed to accelerate the best thing of a portion of his equity awards and so the accounting typically spread over the required service period in the future. So let's say three years, if thats what the vesting period is.
And since robs now retired we accelerated that in the board granted that and Thats. The additional charge for some of those equity awards and that increased compensation.
That makes sense.
It does yes. Thank you.
And with regards to das instruments versus.
Services I mean, I think we saw good mix I kind of mentioned it earlier in das So greater pharma biotech greater reagents software was great. So our informatics business did extremely well just bio continues to do very well.
So the mix in that business was positive applied markets were flat. So overall, we're seeing a bit improved mix change to greater service software and reagents in that business, which helped contribute to.
If you see the gross or the margin expansion and so 340 basis points in the quarter.
Okay, and then if I could just squeeze in one last one just Jamie how are you thinking about the there's you know it seems like there a couple of different moving pieces within the earnings guidance for this year have you broke it out or could you walk through how you're thinking about kind of EPS bridge versus your old guidance to guidance today. It just seems like your tax rate moving around organic growth.
Moving around bariatric moving around et cetera.
Yes, I mean, if I were to simplify it going up three cents is largely on the back of extra margin expansion. So I'd call that kind of up six to seven cents versus our prior guidance for the rest of the year organic growth is coming down so 5% versus kind of five to six organic guidance range, so that maybe down 4% to 5%.
So up two cents margin versus organic growth.
And then really all the other items FX is a headwind of two cents in tax and interest expense is probably better by three cents. So that gives you maybe an extra penny as well so greater margin expansion offset more than offsetting organic growth a shortage here.
And a little bit extra tax benefit more than offsetting foreign exchange.
Perfect. Thanks, Jamie.
Thank you.
And your next question comes a lot of Tyco Peterson from JP Morgan. Please go ahead.
Hey, thanks.
I wanted to dive into the margins a little bit more you did have a restructuring during the quarter can you just talk on how much of that was from kind of the the risk versus stuff that had been in the works ahead of the quarter and then.
Think about.
Next year, you're sticking with high single digit organic growth targets by the lower base. This year I just wondering how you think about the comfort level.
Yes, so maybe I'll touch on restructuring first so I mean not much of this has been planned.
So it's really into broad areas. One is our services organization I've I've mentioned in the past that we've invested in a software platform called Servicemax, which basically allows us to schedule and dispatch our field service engineers better control contract control pricing et cetera. So we've known that that's been invested in over the last.
Couple of years and up and running well. So we were able to do a little bit of Rightsizing in our services organization and then the other part was also related to the reorganization of a company. So we think of the company transformation much more as a growth oriented change, but it definitely provided a little bit of synergy as well and that those two things really.
Comprise the restructuring charge.
In terms of the high single digit growth next year I mean, 5%. This year is still strong we still think a lot of the organic growth accelerators.
We'll come next year and some of these things that are going on right. Now is timing. So I think you know we mentioned applied genomics is still a strong market some of that backlog, we see visibility to in 2019 2020.
Perkinelmer genomics testing item is a short term issue as we transfer from one facility to a different facility. It's not a demand issue in fact, we happen to turn away demand.
And das we expect.
It did improve quite a bit so das came from 2% to 4%.
We'd said, 5% academic government came through one source came through.
But the applied markets, we're still a little bit softer than we anticipated I think if you head into next year Vantages hasn't contributed a lot this year cannabis and all of our both accelerators, we think will kick in even more so we're still quite confident in the future trajectory here.
And then a question on the China strategy here around food Theres, obviously, a lot of turmoil you alluded to that your comments can you just talk to you know your visibility into that market.
You know and how what's the strength of upstream versus downstream for you guys and and what's your comfort level that you won't run into some of the problems with privatization that we've heard about from somebody other.
Yeah I.
I mean, I think the number one thing that to point out is that from me. Thanks perspective, they have very strong hold on the local customers and 70% to 75% off their revenue comes from consumer Bose CES not playing in that get ready capital intensive market. The installed base is already there they are providing more off because.
Zuma Bose and that he Asians, so that trajectory is one that we haven't seen slowing down while we've been talking to May sang and again. This time to do that we have used for this acquisition was not dissimilar to what we've done with you I mean assessed by will be bought covered the principal owner for more than Oh, you ought to have.
And I understood on studied the market. So we feel really good about it.
All right and then one last one for Jamie just on cash flow 95 million or shows year to date can you just talk on.
Where do you think that that could be headed as we think into next year I'm just curious if theres an opportunity to improve on that.
Yes, I mean, if I step back and just talk about cash that a little bit I mean, if you go back a few years I think it's clear that the company has been focused on improving our revenue growth and expanding our margins I think we've done a lot of things to do that we've changed incentive plans weve leaned into working capital to better serve our customers.
We've invested in capital expenditures in euro immune and other parts of PK Guy and we felt that during that time period, which is important to change the trajectory of the company and it also happen that coincide with the low interest rate environments that we thought it was a good trend.
As we look forward I mean, certainly we understand that all three metrics have to go well together, so increasing our growth rate increasing our margins I think we've been able to prove that over the last couple of years I think cash flow will come along well so I'm confident in an improving but I think it's going to take a little bit of time, it's not going to be an overnight.
Change, we've got some things underway.
In some process improvements underway.
Partially in the areas of receivables and inventory I think if you look year to date Capex is down 10%. So that was an easy one to help fix or a invested a little bit differently and say.
So I think its confident I won't guide on next year, but a very confident that we will get this up to 90% plus business.
Okay, Thanks, and best of luck with everything Rob.
Thank you.
And we have a question from a lot of Steve Beuchaw with Wolfe Research. Please go ahead.
Hi, Thanks for the time here I'd echo the the well wishes roxland great working with you.
Thanks.
I guess, what I'd like to do at first is just.
Probably for prolonged is asks if you could give us a little bit of an update on some of the commercialization efforts around bantered us I think it's a two parter. One is have you seen progress on Validus reimbursement in Europe , and if not can you talk talk about like when you might be ready to talk about progress there and then.
We saw the of course, the news about the Validus strategy in the U.S. and Asia you mentioned it in the prepared remarks I just wanted to clarify I mean do you still intend to seek FDA approval CA F.C. FDIC approval for randomness to to work on that as a system that goes into both of those markets as something that people.
We will run on site and then between now and then are you taking them at meaningful number of samples as something of an LDC and then I have one follow up.
Sure.
We started with the regulatory strategy in the us on China Synta U.S., our strategy is not going to be dissimilar to our peers, it's going to be unarguable under a CLIA. It would be an NBP dislike most of the other tests on that we currently we do not have any plans to go under up you may or get done a regulatory approval in the U.S.
In China, VR pursuing cfd, a oh regulatory approval via Dunbar type testing, we are in the process off our clinical clinical trials and that's a big it's due course and time so from a regulatory perspective, that's our strategy in the U.S. the benefit that we have.
I have is we will be able to differentiate in terms of providing preeclampsia and carrier screening and providing it as one best.
So it results in a better customer experience as there's only one brick and one report out in a simplistic manner to our customers. So thats from a regulatory perspective in terms of you you reimbursement strategy that is mostly controlled by the country's read it does operated as you know some countries initially.
Have you have already put the system and that is government approval around 250 euros. So that is already available and it's out there. It's not a specific branded this code, but it is available for and IBP reimbursement.
So that's from your perspective feedback that we continued to get from our customers is the ease of use workflow automation and obviously cost is an important factor and again, Steve as we've said earlier our focus this year is to ensure that we get party installations.
Make sure that they work flawlessly and I'm not customers President and published from there.
Okay. So sorry, if I am being a little dense but is it indicates that you don't believe there's any additional work you need to do to get reimbursement in Europe .
In Europe no.
Okay, Great and then my follow up is actually going back to a point that came up on last quarter's call, where there was a discussion around some some back and forth in China dynamics that popped up there were some tenders were pulled away just wonder if I could get an update on how those dynamics are progressing and if you got any of that back and then maybe as a.
Corollary to that more in the diagnostic side in China, how you're seeing that sort of pricing competitive dynamics. There. Thanks again.
So let me let me take the first one on the tender again, the tender was already small one it was really not that material and probably got.
Littered much more attention than it should have a so I don't think it is significant and now for us to talk about any did not materially impact what we are what our businesses in China, specifically now switching to your second part around diagnostics in China, Despite low bought trades in China.
Now I'd be productive held franchise continues to do well I'd Immunodiagnostics franchise continues to do both cinema, Jimmy what was occupancy diagnostic.
Oh, yes, upped up mid single digit was up mid single digits Sobi.
Steve from a diagnostics perspective, China continues to do well for us.
Okay, Great again, thanks really appreciate it.
Yeah.
And your next question comes from the line as Doug steam goals of Cowen. Please go ahead.
Thank you and Rob Thanks for all your efforts and good luck in your next chapter.
Thank you.
So I guess three or four questions starting on D.A. us how impactful where are the three transitory dynamics you pointed to in Q2 or that you expect it to reverse in the third quarter.
One of those is the one that Steve just asked about the the $4 million than revenue you didn't book in Q2 due to the trying to import approvals Saab I take your expected half of that to come back the second was.
Expected changes you made in the academic government leadership team is having the potential of or reverse switch reverse what was a headwind in the first half what revenue declined 10% year over year and the third was Dom and enterprise services backlog converting.
You thought that could give you a 50 to 100 basis points of growth. This quarter. So I'm curious if you could just provide updates on those things within deal yes.
On diagnostics I think you attributed that Q3 moderation in diagnostic growth relative to trend to a couple of things you positioned as one timers such as lab consolidation.
I'm just wondering if there are one timers why why doesn't full year guidance imply that the that comes back in the fourth quarter.
On.
Third is on 2020 targets pull out I know, you're not need a PK I, but you're you're going to be due to the CEO role.
Based on changes response to want to tyco's questions that it looks like you're good what the 2020 financial targets that Rob outlined a few years ago I just want to make sure. That's right and my last question is on free cash flow conversion last quarter, you set new adjusted free cash flow conversion guidance to around 80%.
Is that still the case thank you.
So since we were pretty furiously, writing down to make sure they didn't forget.
Yes, I'll chime back yet if if if I went to fast sorry about that.
Let me go with the one that was for me because the other three low for Jamie. So let me take the one around 2020 CEO , but as to die cost question. You know I don't want to give guidance on 2020, we'll be happy to do that as we.
Get to our Q1 call, but I really look forward to Tyco's conference in San Francisco and be able to give more of an update on our strategy and how we see next year on the next several years coming in but what I will say that art pieces holders are brought back solicitous continue to do very well and we're very confident and.
We have talked about earlier in the yard.
Yeah, Hey, Doug.
So first one with regards to Das bridge from the first after the second half here. So I would say two to three of those came through as expected. So that together academic and government did turn around as anticipated we definitely so significant uptick versus the first half being down over double digits. As you mentioned one source I had mentioned that we definitely had visibility too.
A lot of this backlog so that did see an uptick as well.
And then the applied markets did not though so that's why we're at 4% versus 5% applied markets continues to be soft. So probably you know we did mention some of our food npis. Those actually are performing pretty well are better than the first half that said the overall market is just not where we see it to be.
And I think you called out the China items on MOFCOM, or maybe the tenders or whatnot, but I.
I think that such a small amount now we just talked to the overall applied markets and that has not recovered as we talked about earlier.
Second on the Dx bridge in the third quarter versus the fourth quarter with regards to lab consolidation. So late in the third quarter, we did start or move into a different facility.
That will impact the fourth quarter as well, which we that's why we're guiding similar organic growth rate heading into the fourth quarter. This is not a demand issue as I mentioned earlier, we have plenty of demand.
And we are actually having to turn away samples just big as we kind of pull through this so it will impact the fourth quarter, but we anticipate heading into 2020 will be fine.
And then last one around free cash flow, yet, we said, we called out 80% not coming off that I would say if you look at the fourth quarter.
Theres really two areas that we've got a lot of focus on one is it's our highest sales quarter. So inventory does normally deplete through the quarter here and we fully expect that as well. We've also done a lot of work around demand planning to make that better and then receivables receivables needs a lot of focus.
As I mentioned earlier it is not a turn of the switch here, but we've got a lot of good actions in place both from a billing process perspective additional resources, calling on customers engaging our commercial teams. So we're still hoping that 80% is still the right answer here, but we are it's a lot to do in the fourth quarter here.
Okay. Thank you very much.
Thanks, Doug.
Your next question comes the line as Brannan collateral with Jefferies. Please go ahead.
Thanks, Good afternoon.
Maybe for holiday just on the Amazing acquisition can you talk about what technologies. They have that you didnt already having the perkin portfolio and.
What's proprietary about any of the technology, if anything and when they are what timeline do you have to perhaps take some of those outside of China for the export market.
Yes. Good question, Brandon I think from a technology perspective more than the uniqueness in the technology that they provide what it was important for us that they had the regulatory approvals and they already had the products in the marketplace. So it was not that there was significantly you know a unique technology a differentiated to dose the ability to have a broad.
Product portfolio that they had taken through the regulatory approvals and of course entrenched in the marketplace. I think the most important fact was the second point that you pointed out Brian .
Ability for us now too big a product portfolio and combine that with our existing product assets a food assets from Bayou does time department acquisitions allows us to present, a more comprehensive workflows solutions to our customers not just in China, but also in other markets.
Thanks to know two part question for Jamie the corporate expense step down quite a bit to about 13 million in the third quarter said that a good run rate to kind of assume going forward and then could you give us the impact of FX on the gross and operating margin lines in the period. Thanks.
Yes, I mean, I think in general our overall cost bases are pretty similar cost base, we expect moving forward into the fourth quarter I mentioned, there is a little bit of timing.
So I don't know the exact split off my head between corporate or the divisions, but we had a little bit a timing and R&D, which probably shouldn't hit the corporate milestone the little bit of extra marketing expense that we line. So there's probably a slight uptick there in the fourth quarter, maybe some of that comes to corporate.
And then with regards to foreign exchange I think it was 20 basis points on the gross margin line in the quarter, which flowed through to the same amount in on the operating margin line as well.
Great. Thanks.
Thanks.
Your next question comes the line as BJ Kumar with Evercore ISI. Please go ahead.
Hey, guys. Thanks for taking my question, Rob up you know congrats on a carrier itself. It's closed central that that this is my first call in happens feel lashing out for a lot and maybe this is going to get journey for us.
This be or I guess first call up.
Coming in as the inbound CEO submit maybe I'll start with that the 2020 outlook questions. If the base business here, we're looking at doing mid singles.
Is it quite a thing that the key to get to high singles for Nextshares Atlanta, This and not the food business on the cannabis sites.
In between those two drivers if I'm going to write Frac.
And.
Is there is there one or is this the other which is going to be a more significant driver for from a 2020 perspective and for 2020 should we be assuming some of these applied markets or macro or any of those end markets, maybe improving or should that be stable.
Where they are right now.
So rich I look forward hopefully to a long journey together, but I think the answer to your question without specific guidance is that the resilience now as we have realigned our portfolio is that that is not one growth driver. You know that are about seven to growth extra that it does that we have that Vietnam.
Now becoming dependent on any one picking expanded this euro immune our enterprise business genomics cannabis. We've got several growth live ours that gives us the level of confidence that those will continue to act as growth accelerate does for us.
Gotcha, and then maybe one on the balance sheet inventories SAP seems like it's that kicked up and maybe up this is not some of this as timing issues given the acquisitions, maybe comment on not inventories.
Yes, so youre right some of that is.
M&A related but I think year to date, it's about a $45 million cash flow usage, I think and a lot of that is.
Seasonal so if you look at the last few years, it's similar where we build in the first half and kind of get ready for a larger second half. So a large part of that is seasonable. Some of that as choice you know I mentioned that weve invested in.
Working capital to improve our customer experience so.
BJ on prior calls I've talked about our distribution center strategy, which than we think is going well and I think as we turn into 2020 thats something that hopefully we can start to depress the level of finished goods that we have on hand, but some of that's a choice in terms of how the fill rate and how quickly we service our customers and.
But overall that number that you're seeing year to date should come down substantially in the fourth quarter.
Okay. Thanks, guys.
Your next question comes from line of Damn brand ended with FBR. Please go ahead.
Great. Thank you Rob Congrats it's been great spending time with you're working with you through the years. Thanks Dan.
So so maybe it's a lot just maybe an early question I know, it's you know.
First quarter in here or really first call him an investor interest in any early insight about the type of.
No different perspectives that you might bring to the CEO role.
I think there.
I would say rather than say different I would say you would probably look on building on what Rob has done and that has to do you guys. I think in if you would look at this from a differentiation perspective is the focus on bringing the organization together you know, bringing the come on the commercial an alignment which has already happened now.
Now gives us more bad with door to push our work flow solutions across end markets, leveraging a combined or commercial organization. So I think that's a big or the that's a big I would say a.
Differentiation that we are implementing and which has been completed now.
The second aspect I would say is as we look forward is a lot more focus on technology.
Continued to build on innovation I would say those are the two areas, but you probably will.
See some differentiation.
Great. Thank you for that.
So maybe I don't know Jamie I guess, just on Das I know I know, it's come up a few times, but just on the applied weakness I guess, what gives you the confidence that you captured this in the trend with the New guide and anything we should look out to help us assess kind of when maybe some of this weakness will turn whether its PMI is there any end market indicators you can help us with.
Thanks, Dan I mean, I think what we're guiding here is a pretty similar to though that the last three quarters really that's been 5% every quarter I think applied markets in general has been flattish for the entire year and so we aren't embedding really at this point any additional uptick on the das side I think it's kind of be more of the same in the fourth quarter here really is the way to answer that.
Great and then maybe final one just on the deal on the measuring deal I guess I mean, I apologize if I Miss has put a was this a competitive deal.
Any color how long it on the company for.
See I think you mentioned, 25% growth in the prepared remarks back to Onein, but how should we think about what's a reasonable level of growth going forward and then the final one is I think post the deal now your China exposure is close to maybe 25% or so.
Time on the countries the relations or souring, a bit and the company seemed country seems excuse me seems to be getting more in would looking so I guess, how do you think about coming from a control perspective, just having such a big portion of business over there like any changes or additions you need to make sure you're staying on top of things over there. Thank you.
Yeah, So maybe I'll talk about the deal the daily piece for US again. It is very similar to the ones that I think I mentioned it earlier very similar to what we have done vince's by you on your two immune is you know it was not competitive in fact, the principal was not looking at that divesting the company, but we worked with him for.
About 18 to 24 months and convinced him that a partnership with US is probably the best interest for him and for his business. So that's too that in terms of.
China per se for Oh, sorry, going back to the growth aspects. We expect this to continue to grow at but how do we face off about 20% plus over the next few years because.
It's really got a unique product portfolio lock more focus on consumer Bose and that gives us.
The confidence that did we continue to have traction.
On the part aspect on China, and the the noise around it.
I feel and then we feel very confident that this is essentially eventually even the nice nice slows down things are going to go back to being normal from our perspective again, we have not seen any discernible change in in our in our in our business there.
There might be one or two noises euro there, but that has no discernible change our strategy in China in China for China, and that has worked value for us over the past decade of December bio and how you on acquisition and we see it to be no different formation.
Great and wanted to that.
And so that the amazing business is 30 million in revenues, so that should increase it by about 1% and we're right around now about 20%.
Excellent okay. Thanks, Jamie appreciate it.
<unk>.
And our final question comes in a lot of Bill Quirk with Piper Jaffray. Please go ahead.
Great. Thanks, Good afternoon, Rob, obviously, best best Lucky and future and congratulations to prolong thank you.
So I guess couple of questions first off with respect to the I think a couple of comments Jamie's made about turning down business on the diagnostic lab side of things can you just give us a little comfort that as you consolidate into Pittsburgh.
Help us think about any sort of capacity expansion that you'll have their such that you're not turning down volume and if so when when is that and then I have a fall for that thanks.
Maybe I can pick that one then and now as to be about as far as we look at as we look you know I mean.
Just talking more specifically, we had two or three no was six which we're in now and brand for just getting them backed up moving them revalidating them and getting them up and running it's the process more than anything else from a funded perspective, you know the issue here is not.
Having you know, making sure that we have a strong front of the issue here is to just getting those milbus seeks backing a installing them validating them and getting them up and running from a capacity perspective, I don't think that from a 2020 to 2021, we are going to have an issue that.
From off capacity utilization and you know again building our as a we do the.
Vanda This tour in Pittsburgh, you will have an opportunity to see our to see the infrastructure and lab there.
Ourselves.
Okay perfect I appreciate the clarification and then I guess is staying in diagnostics can you remind us where we are on a year on the on ft, a approvals, but in other words kind of what percent of the portfolio. At this point is through Sta and if we're not all the way there again, maybe you can give us a road map in terms of when Youre closing.
I mean has effectively an equivalent portfolio on you asked what they have in Europe . Thank you.
Well I think it'll probably take a couple of years before it has the same level Oh approvals in the us that had passed from CE Mark perspective, but at this point.
Initially if you recall post a poster close when new approvals would come through we would you know we would send out to trade release, but now you know these happen every couple every quarter, our three or four every six months of you've stopped doing that and we've essentially stopped tracking and the business. There is a smaller brace it's growing its doubling every year and.
We continued to see a see it as a one of the fastest growing markets for uranium and I don't think thats going to slow down in the near future.
Got it thank you very much.
Yeah.
And Weve reached the top of the hour I'll now hand, the call back to Rob sale for closing remarks.
Great well first of all the thanks, everyone for your questions and continued interest in Perkinelmer.
It's been a genuine privilege to lead the company over the last 12 years and I'm proud of what we've achieved but proudest still with the people who carry our mission forward in the years to come as as I mentioned before I think the companys.
Very well positioned from a financial perspective, but also to provide important solutions that help create healthier families and improve the health and longevity for people around the world. So I truly believe the best days are ahead for Perkinelmer and I look forward to celebrating the ongoing success.
Good night and have a great evening.
Ladies and gentlemen. This concludes today's conference. Thank you for your participation and have a wonderful day you may all disconnect.
Oh.